Abstract
Objectives To evaluate the association between smoking behavior and type 2 diabetes risk using genetic data.
Research Design and Methods We obtained summary data from genome-wide association studies (GWAS) related to smoking behavior (n=1.2 million people) and type 2 diabetes (n=898,130) in individuals of European ancestry. Mendelian randomization analysis was performed using these summary-level statistics. Specifically, we assessed if genetically determined smoking initiation, smoking cessation, and smoking heaviness (number of cigarettes per day) modulated susceptibility to type 2 diabetes.
Results We observed that for each 2-fold increased odds of initiating smoking behavior corresponded with a 21% increased susceptibility to type 2 diabetes (OR = 1.21, 95% CI: 1.18-1.24, P=1×10−12). Our effect was consistent across instrumental variable methodological approaches, and we did not observe evidence of systematic biases to our effect estimate. When analyzed using an analogous approach, we found that the effect of smoking initiation increasing diabetes risk was equivalent to the effect of smoking behavior on increase coronary artery disease, an established causal risk factor for cardiovascular disease.
Conclusions Genetic data supports the hypothesis that smoking initiation corresponds with increased risk for type 2 diabetes. These findings are consistent with previous clinical epidemiological association between smoking behavior and elevated type 2 diabetes risk. Individual-level MR studies are necessary to estimate mediators and confounders related to this association.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by R56DK101478 and R01HG010067 (BFV), a Linda Pechenik Montague Investigator Award (BFV), T32HD043021 (CST), and an American Academy of Pediatrics Marshall Klaus Neonatal-Perinatal Research Award (CST). All authors confirm independence from funders and that all authors had full access to all of the statistics in the study. As such they can attest to the integrity of the data and the accuracy of the data analysis.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used for this work utilize summary data that is available in the public domain.
